Views & Analysis | Perspectives on pharma industry issues

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Articles

Helping the patient in rare disease areas

How can rare diseases get the right focus they need? Geoff McDonough, from Genzyme, talks to pharmaphorum about the challenges and opportunities of this space. Hardly a day goes by when we don’t hear something about the most common diseases of our time – heart disease, diabetes, major cancer types such as…

Articles

How times have changed…

With 30 years experience in pharma, Neil Dickinson reflects on the changes he has seen in the industry. I started out in the pharma industry in the early ‘80s as a GP rep in west London with a call rate of around six doctors in a typical morning. Selling a…

Articles

Adapt or die time for UK pharma

The impact of UK NHS reform could resonate globally on pharma so it’s time to prepare for change. pharmaphorum spoke to Mike Sanvoisin, of IMS Health, to hear what’s in store. NHS reform might seem like an issue local to the UK, but the world is watching with interest to see how pharma reacts. Under a barrage of criticism from...

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology